deliv organ revenu growth ep beat allow
compani favor revis full-year guidanc concern currency-rel
oper margin hit eas currenc still tailwind fiscal margin
expans drove improv oper margin reiter
think stock setup remain attract
project organ revenu growth rang cvg expect
grow rtg mitg show growth rang diabet sale
improv around compani also anticip oper margin improv
modestli higher bp project full year result impact
hurrican maria infus set recal non-gaap ep manag
target rang call higher tax rate fx headwind
current rate unfavor expect time
call april addit currenc neg impact revenu roughli
oper margin slight benefit although
year-over-year revenu growth comparison challeng back half
fiscal year rel first half compani express confid oper
momentum experienc bode well strong perform
alreadi incorpor favor prior-year comparison price target
share move previous new target deriv
multipl appli forward year ep ebitda forecast respect
multipl still repres discount mdt large-cap medic devic peer
group consid stock setup attract compani major near-term
catalyst favor updat tct nass meet next
encourag fiscal guidanc revis
rais guidanc fiscal organ revenu growth rang
previous foreign exchang rate remain constant compani
expect fiscal revenu neg affect roughli
deeper hit previou expect ep maintain
prior target repres year-over-year constant currenc
growth previou rang includ benefit foreign
exchang move zero benefit given current exchang rate view
project like conserv expect see out-performance balanc
year
pleas see page report import disclosur
outperform rate driven optimist outlook
sustain mid-single-digit top-lin growth trajectori combin mdt/cov
entiti combin cost synergi tax rate improv expect
new meet/exce goal grow adjust ep faster
revenu expect pipelin growth driver like becom focu investor
product contribut meaning first full year commerci
view new continu top-tier top- bottom-lin growth
perform medic devic space
on-going launch new product
resolut onyx
maintain de market share
us
stabil us spine
strong adopt corevalv us
return growth spine franchis
out-year top-lin growth acceler
market share loss
continu deterior spine
weak adopt trend new product
diversifi medic technolog servic solut compani presenc
countri combin entiti covidien
merger new oper four segment cardiac vascular group
minim invas therapi group diabet restor therapi group cardiac
vascular group segment manufactur market device-bas medic therapi
cardiac rhythm heart failur crfh coronari structur heart aortic
peripher vascular mitg focus advanc gener surgic technolog
diabet segment manufactur market device-bas medic therapi diabet
restor therapi group segment manufactur market device-bas medic
therapi spine neuromodul surgic technolog
revenu came ahead cowen forecast
consensu estim cardiac vascular group cvg revenu vs
estim minim invas therapi group mitg revenu compar
consensu restor therapi group rtg revenu vs
project diabet group revenu easili exceed street
target compar constant currenc basi cvg grew mitg rtg
improv diabet increas mdt top-lin strength consist
across geographi growth growth ou develop
market growth emerg market
within cvg sale coronari structur heart busi improv
constant currenc basi help highteen constant currenc growth tavr
global strength evolut result coronari also promis high
single-digit sale growth driven double-digit constant currenc growth drug-elut
stent guid cathet
result mitg highlight constant currenc growth surgic innov
help low double-digit growth advanc mid-single-digit growth
rtg spine sale growth brain therapi revenu increas
ent demonstr mid-single-digit growth pain therapi sale improv
thank growth pain stimul
lastli within diabet advanc insulin manag growth exceed constant
currenc basi growth thank compani continu success
launch system addit continu experi increas
sensor attach rate also help fuel diabet divis best quarterli
perform decad
free shine quarter
gener quarter repres convers ratio
adjust inclus post-tax amort compar
entireti convers ratio result part due
improv account receiv account payabl believ on-going
initi priorit gener well receiv investor
also indic call still expect return annual free cash flow
sharehold annual guidanc unchang litig headwind
dissip recogn benefit program put place improv work
capit intern emphasi convers reiter call note
spent entir day topic quarterli busi review also remind
investor annual incent compens tie success achiev free
cash flow benchmark topic strong free cash flow gener natur beg
question option manag indic focu remain
organ growth invest remain activ opportunist tuck-in acquisit
strong quarter gener kick-off year believ manag gain
credibl roadmap forward appropri reward continu
margin ep disappoint either
deliv strong organ growth perform exceed estim
accompani oper margin print better
street forecast mdt adjust om constant currenc
basi fx posit impact bp thu constant currenc basi oper
margin expand adjust gross margin bp year
year vs revis number compani maintain oper
margin guidanc impli bp yoy expans bp
constant currenc reiter om guidanc reveal fx continu
tailwind report om perform allevi concern
strengthen dollar could dampen report margin expans trajectori
continu view fiscal margin target ration expect reset
annual expans goal laid lrp june investor day
ep came cowen forecast
consensu estim beat driven top line om outperform
part due favor tax rate vs estim
compani report thomson eikon cowen compani
mm exclud chgvariancerptdrptdrptdrptdrevenu cardiac rhythm heart structur monitor constant currenc revenu organ constant currenc revenu good interest expens share quarteractualscowen estimatesconsensusprior year cowen
compani report thomson eikon cowen compani
medtron plc revenu build mm fiscal year end april year end april y/i y/i ex-fx y/i y/i ex-fx y/i y/i ex-fx therapi y/i y/i ex-fx y/i develop y/i y/i ex-fx y/i y/i ex-fx y/i ex-fx impact impact cowen compani estim compani file transcript cowen
compani report thomson eikon cowen compani
medtron incom statement mm except per share y/i y/i cc good incom non-oper expens tax net dilut share y/i tax net y/i item tax net y/i cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
continu util pressur account organ play bigger
role health care deliveri competit dynam global potenti regulatori delay
reject failur devic clinic trial econom sensit price pressur
and/or weaken consum demand develop market econom and/or polit
uncertainti emerg market intellectu properti challeng
continu util pressur competit dynam global potenti
regulatori delay reject failur devic clinic trial econom sensit
price pressur and/or weaken demand develop market econom and/or
polit uncertainti emerg market electrophysiolog clinic commun deem
st jude medic durata lead safe effect yale independ review infus
biolog cite cancer promot effect fluctuat foreign exchang rate
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
